tiprankstipranks
Trending News
More News >
Nektar Therapeutics (NKTR)
:NKTR
Advertisement

Nektar Therapeutics (NKTR) Stock Statistics & Valuation Metrics

Compare
1,482 Followers

Total Valuation

Nektar Therapeutics has a market cap or net worth of $390.31M. The enterprise value is $111.46M.
Market Cap$390.31M
Enterprise Value$111.46M

Share Statistics

Nektar Therapeutics has 17,301,062 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding17,301,062
Owned by Insiders1.09%
Owned by Institutions28.13%

Financial Efficiency

Nektar Therapeutics’s return on equity (ROE) is -1.96 and return on invested capital (ROIC) is -40.02%.
Return on Equity (ROE)-1.96
Return on Assets (ROA)-0.39
Return on Invested Capital (ROIC)-40.02%
Return on Capital Employed (ROCE)-0.43
Revenue Per Employee1.61M
Profits Per Employee-1.95M
Employee Count61
Asset Turnover0.32
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Nektar Therapeutics is ―. Nektar Therapeutics’s PEG ratio is ―.
PE Ratio
PS Ratio0.00
PB Ratio0.00
Price to Fair Value3.15
Price to FCF0.00
Price to Operating Cash Flow-1.88
PEG Ratio

Income Statement

In the last 12 months, Nektar Therapeutics had revenue of 98.43M and earned -118.96M in profits. Earnings per share was -8.70.
Revenue98.43M
Gross Profit67.74M
Operating Income-105.20M
Pretax Income-119.20M
Net Income-118.96M
EBITDA-86.70M
Earnings Per Share (EPS)-8.70

Cash Flow

In the last 12 months, operating cash flow was -22.60M and capital expenditures -12.61M, giving a free cash flow of -35.21M billion.
Operating Cash Flow-22.60M
Free Cash Flow-35.21M
Free Cash Flow per Share-2.04

Dividends & Yields

Nektar Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta3.73
52-Week Price Change24.30%
50-Day Moving Average18.70
200-Day Moving Average14.97
Relative Strength Index (RSI)50.77
Average Volume (3m)2.23M

Important Dates

Nektar Therapeutics upcoming earnings date is Aug 7, 2025, After Close (Confirmed).
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date

Financial Position

Nektar Therapeutics as a current ratio of 4.26, with Debt / Equity ratio of 730.36%
Current Ratio4.26
Quick Ratio4.26
Debt to Market Cap0.10
Net Debt to EBITDA-0.67
Interest Coverage Ratio-3.74

Taxes

In the past 12 months, Nektar Therapeutics has paid -239.00K in taxes.
Income Tax-239.00K
Effective Tax Rate<0.01

Enterprise Valuation

Nektar Therapeutics EV to EBITDA ratio is -2.88, with an EV/FCF ratio of -1.41.
EV to Sales2.54
EV to EBITDA-2.88
EV to Free Cash Flow-1.41
EV to Operating Cash Flow-1.42

Balance Sheet

Nektar Therapeutics has $218.63M in cash and marketable securities with $100.34M in debt, giving a net cash position of -$118.30M billion.
Cash & Marketable Securities$218.63M
Total Debt$100.34M
Net Cash-$118.30M
Net Cash Per Share-$6.84
Tangible Book Value Per Share$4.43

Margins

Gross margin is 74.61%, with operating margin of -106.88%, and net profit margin of -120.86%.
Gross Margin74.61%
Operating Margin-106.88%
Pretax Margin-121.10%
Net Profit Margin-120.86%
EBITDA Margin-88.08%
EBIT Margin-92.54%

Analyst Forecast

The average price target for Nektar Therapeutics is $95.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$95.80
Price Target Upside324.65% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast-3.24%
EPS Growth Forecast31.00%

Scores

Smart Score7
AI Score50
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis